Coya Therapeutics (NASDAQ:COYA – Get Free Report) released its quarterly earnings results on Tuesday. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.14, Zacks reports.
Coya Therapeutics Trading Down 1.7 %
Coya Therapeutics stock traded down $0.11 during trading hours on Tuesday, reaching $6.74. 3,384 shares of the stock were exchanged, compared to its average volume of 96,359. The company has a market cap of $112.54 million, a P/E ratio of -10.36 and a beta of 0.31. Coya Therapeutics has a twelve month low of $4.75 and a twelve month high of $10.42. The stock has a 50 day moving average of $6.29 and a two-hundred day moving average of $6.48.
Analyst Upgrades and Downgrades
Several equities analysts recently commented on the stock. Chardan Capital restated a “buy” rating and issued a $14.00 price target on shares of Coya Therapeutics in a research note on Thursday, February 6th. D. Boral Capital restated a “buy” rating and issued a $18.00 price target on shares of Coya Therapeutics in a research note on Tuesday.
About Coya Therapeutics
Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.
See Also
- Five stocks we like better than Coya Therapeutics
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- 3 Must-Own Stocks to Build Wealth This Decade
- Golden Cross Stocks: Pattern, Examples and Charts
- Advanced Micro Devices Eyes AI Market Growth—Is AMD a Buy?
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Is Viking Therapeutics the Next Blockbuster GLP-1 Stock?
Receive News & Ratings for Coya Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coya Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.